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Abstract
Arterial hypertension and stroke are strong independent risk factors for the development of cognitive impairment
and dementia. Persistently elevated blood pressure (BP) is known to impair cognitive function, however onset of
new cognitive decline is common following a large and multiple mini strokes. Among various forms of dementia
the most prevalent include Alzheimer’s disease (AD) and vascular dementia (VaD) which often present with similar
clinical symptoms and challenging diagnosis. While hypertension is the most important modifiable vascular risk
factor with antihypertensive therapy reducing the risk of stroke and potentially slowing cognitive decline, optimal
BP levels for maintaining an ideal age-related mental performance are yet to be established. Cognition has
improved following the use of at least one representative agent of the major drug classes with further
neuroprotection with renin angiotensin inhibitors and calcium channel blockers in the hypertensive elderly.
However, a reduction in BP may worsen cerebral perfusion causing an increased risk of CV complications due to
the J-curve phenomenon. Given the uncertainties and conflicting results from randomized trials regarding the
hypertension management in the elderly, particularly octogenarians, antihypertensive approaches are primarily
based on expert opinion. Herein, we summarize available data linking arterial hypertension to cognitive decline and
antihypertensive approach with potential benefits in improving cognitive function in elderly hypertensive patients.
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Background
The relationship between high BP and cognitive dys-
function has generated great interest and broad investi-
gation over the past few decades [1, 2]. While concerns
have raised over cerebral perfusion, blood flow and BP
levels in the elderly, particularly following a stroke, there
is limited evidence whether the prevention of dementia
or slowing cognitive decline is associated with the BP re-
duction per se or specific drug properties [3–5]. Demen-
tia represents one of the major and growing global
public health problems affecting approximately 47.5 mil-
lion people worldwide with 7.7 million new diagnosed
cases every year (http://www.who.int/mediacentre/fact
sheets/fs362/en/). It has been estimated that the annual
global dementia-related healthcare cost was 604 billion
dollars in 2010 [6]. AD contributes to approximately
70 % of all cases followed by VaD accounting for nearly
25–30 %. With prolonged life expectancy and the grow-
ing prevalence of uncontrolled hypertension, the world-
wide incidence of patients with dementia is expected to
double by 2030 reaching 75.6 million and rise even fur-
ther to 135.5 million by 2050 [5, 7]. Given the link be-
tween elevated BP and cognitive impairment, an
improvement in BP control may reduce the risk attribut-
able to dementia, its progression over time and possibly
improve patient outcomes. Limited evidence also exists
regarding chronic kidney disease, small vessel disease
and other modifiable risk factors with a specific focus on
midlife hypertension, midlife obesity, midlife dyslipid-
emia or depression to prevent future cognition
impairment.
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Hypertension and cognitive dysfunction related with
stroke
The association between hypertension and stroke-related
dementia is well recognized. Evidence from numerous
studies indicates the development of cognitive decline
following stroke. Dementia has been reported in ap-
proximately 10–30 % of patients 3 months after stroke
[8, 9]. A meta-analysis of 7511 patients indicated that
10 % of patients developed dementia before to first
stroke, 10 % had new dementia directly after first stroke,
and >30 % of patients had dementia after recurrent
stroke [9]. The risk of dementia increased two to five
times following stroke indicating it is a critical contribu-
tor in this scenario [8–11]. The prevalence of cognitive
decline following stroke has been shown to remain per-
sistently high. An observational longitudinal study of
4212 post stroke patients revealed an occurrence of cog-
nitive impairment in 22 % at 3 months, 22 % at 5 years
and 21 % at 14 years of follow-up [12] with cognitive im-
pairment in some patients detected within 7 days which
remained stable 3 months after stroke.
The interaction between brain infarction and the risk
of clinical dementia has been reported in the Nun study
[13]. In this autopsy research, patients with neurological
features of AD and ≥1 lacunar stroke in the thalamus,
basal ganglia, or deep white matter had a 20 times
higher risk of clinical dementia comparing to AD pa-
tients without infarcts [13]. Although arterial hyperten-
sion plays a causative role in cerebral small vessel
disease including lacunar infarcts [14], further studies
need to determine whether maintaining BP control may
prevent from lacunar infarcts and associated cognitive
dysfunction and dementia.
Hypertension and cognitive dysfunction unrelated to
stroke
The relationship between increased BP and cognitive
dysfunction in the absence of stroke is controversial and
not completely understood. Numerous studies have
demonstrated an inverse association between BP levels
and cognitive function. The Framingham Heart Study
has showed that cognitive function was associated with
the basic BP measurement [15]. Among 1702 subjects,
cognitive performance worsened over a 12 to 14-year
period and was negatively associated with initial systolic
(S) and diastolic (D) BP levels. Another study of a total
of 3735 male subjects indicated that midlife elevated
SBP predicted a future reduction in cognitive function
[16]. There was an increased risk for intermediate and
poor cognitive function with every increment increase in
SBP by 10 mmHg irrespective of the history of stroke,
coronary heart disease and subclinical atherosclerosis in-
dicating that BP control in early life may reduce the risk
for cognitive impairment in old age [16]. A further
observation was derived from a study of 2068 individuals
≥65 years demonstrating a U-shaped association be-
tween baseline SBP and DBP and mental decline
assessed after 9 years of follow-up [17]. Elevated baseline
SBP of ≥160 mmHg was associated with a 14 % (95 %
CI: 4–25 %) increase risk of cognitive dysfunction during
9 years of follow-up. Recently, a study of 1115 very old
individuals (85 year and older) showed that cognitive
dysfunction was the highest among participants with
SBP >165 mmHg or <125 mmHg when compared to in-
dividuals with SBP between 126 and 139 mmHg [18]
suggesting the U-curve ratio between BP and cognitive
dysfunction. This could be partly explained by the fact
that age at BP measurements could be related with the
inconsistent associations between BP and cognitive
function.
Optimal BP targets in older adults has become even
more controversial following the findings from the re-
cent longitudinal Milan Geriatrics 75+ Cohort Study
[19]. In this study, 1046 out of 1587 outpatients died
during 10-year follow-up and SBP/DBP of 165/85 mmHg
were associated with the lowest mortality. In contrast,
patients with SBP <120 mmHg and SBP between 120
and 139 (prehypertension) mmHg had 1.64-fold (95 %
confidence intervals, CI 1.21–2.23) and 1.32-fold (95 %
CI 1.10–1.60) higher mortality risk than patients with
SBP of 160–179 mmHg (P values 0.001 and 0.004). Most
interestingly, higher SBP was associated with lower mor-
tality in patients with impaired Mini-Mental State Exam-
ination and Basic Activities of Daily Living [19]. These
findings suggest that patients with impaired functional
and cognitive status may benefit from higher BP levels,
this however merits further clinical research.
The independent association between low daytime
SBP (≤128 mmHg) and a progression of cognitive de-
cline in patients with dementia and cognitive impair-
ment has been recently demonstrated in another study
cohort (mean age 79 ± 5), this however was not observed
in subjects with low SBP without antihypertensive
treatment [20].
Notably, the adverse effects of high BP on cognition
have not consistently been confirmed [21, 22]. This
could be partly explained by inconsistent subject and co-
hort selection including ethnicity and differences in
methods used for the evaluation of cognitive function or
other confounding factors beyond BP levels which may
be additively and synergistically involved in the process
of cognitive dysfunction. Considering the competing risk
exists in elderly subjects, the effects between cognitive
dysfunction and blood pressure may only be modest and
even biased. In other words, only survivors of major ad-
verse vascular events can provide the opportunities for
investigators to observe the relationship between BP and
cognition impairment.
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Nevertheless, persistently elevated BP has been shown
to be an important contributor to dementia [23–25]. A
longitudinal study with a duration of 21 years of follow-
up has supported the concept that midlife arterial hyper-
tension (SBP ≥ 160 mmHg) or high serum cholesterol
levels (≥6.5 mmol/L) significantly increase the late-life
risk of AD, particularly in the combination of these ab-
normalities [23]. Furthermore evidence suggests that
both midlife and late-life hypertension increase the risk
of dementia over time [26]. The negative influence of
midlife BP on dementia has also been showed in the re-
cent Uppsala Longitudinal Study of Adult Men with
40 years of follow-up [27]. In this research, 349 out of
the 2268 enrolled individuals developed dementia over
the longer-term where SBP was found to be a critical
contributor to the elevated risk of vascular and all-type
dementia [27]. The risk was further potentiated by the
presence of other CV risk factors including obesity and
dyslipidemia [27] which is line with previous findings
showing the influence of obesity-associated metabolic
abnormalities on cognitive function [28]. Another study
showed that midlife but not late-life hypertension was
associated with greater cognitive decline over 20-year
follow-up in the recent ARIC (Atherosclerosis Risk in
Communities) neurocognitive trail [29].
However, some studies showed that high BP bore no
relationship with dementia and even suggested that de-
mentia is related to low BP due to J-curve phenomenon
[30–32], particularly in the elderly and very elderly indi-
viduals [32]. While mechanisms linking low BP to cogni-
tive dysfunction are not entirely understood, the death
of neurons in deep brain structures that are responsible
for BP control in addition to physical inactivity and the
fall in BP common in old individuals may play a role in
this scenario.
The association between BP and AD is more complex.
Despite a 40 year follow-up duration, midlife BP was un-
related to the risk of AD in the Uppsala Longitudinal
Study of Adult Men [27]. Similar findings have been re-
ported in other studies [33, 34] with increased DBP as-
sociated with a significantly lower risk of AD [34].
While the role of ethnicity on cognitive decline has
not yet been established, a recent meta-analysis that in-
cluded 28,477 participants revealed that hypertensive
African Americans are at the highest risk of cognitive
limitations (11 %, p = 0.01) when compared to non-
hypertensive African Americans and non-African
Americans [35].
Recent SPRINT trial showed that the more intensive
systolic BP targets of <120mmHg in non-diabetic sub-
jects are superior over the standard systolic BP target of
<140mmHg [36]. In the elderly patients (>75 years), in-
tensive treatment was more effective than standard BP
lowering (HR 0.67; 95 %: 0.51–0.86) [36]. This suggests
that the target systolic BP should be <120mmHg in the
elderly patients. Interestingly, the lower systolic BP tar-
get was beneficial for both the fit elderly and the frail
elderly. However, the highest benefit was in elderly with
average fit status. In the fit elderly hypertensive patients
the HR was 0.47 (95 % CI: 0.13–1.39), less fit elderly HR
0.63 (95 % CI: 0.43–0.91) and the frail elderly HR 0.68
(95 % CI: 0.45–1.01) [36].
The results from the SPRINT MIND trial, which is
part of the SPRINT study [36], will provide answers on
many questions including the optimal target BP value
for prevention of cognitive dysfunction. The primary ob-
jective of the SPRINT MIND trial is to determine
whether intensive BP lowering with target systolic BP
<120 mmHg is associated with a greater reduction in the
incidence of all-cause dementia comparing with a stand-
ard treatment target of 140 mm Hg.
Mechanisms linking blood pressure to cognitive
dysfunction
The mechanisms underlying cognitive impairment are
complex and not clearly understood [37]. Age-related
functional and structural changes in cerebrovascular
small and large blood vessels appear to play a key role in
this context. A reduced number of cerebral cortical ca-
pillaries with thickening and fibrotic basement mem-
branes in addition to changes in white matter have been
found in the elderly [38, 39]. The abnormalities associ-
ated with aging adversely impact brain circulation caus-
ing a reduction in resting cerebral blood flow with
subsequent dysfunction of regulatory cerebral mecha-
nisms [40] which are further potentiated by arterial
hypertension. Subsequently, hypertension-related cogni-
tive dysfunction develops as a result of the imbalance in
autoregulation of cerebral blood flow and cerebral vas-
cular alterations.
In addition, arterial stiffness may explain the associ-
ation between hypertension and cognitive dysfunction
[41] and provide explanations for the conflicting obser-
vations. Namely, the authors stated that increased arter-
ial stiffness is better predictor of cognitive decline than
BP level and proposed that arterial stiffness might be a
target in the prevention of cognitive decline in hyperten-
sive patients. Cooper et al. reported that relationship
between aortic stiffness and cognitive function in
older adults is the consequence of damage in cerebral
microvascularisation and microvascular parenchymal
injury [42, 43].
A recent study in elderly subjects has demonstrated a
decreased temporal and occipital brain perfusion, total
and regional cortical thickness in participants with
hypertension when compared to those without hyperten-
sion [44]. The negative impact of hypertension on total
brain perfusion remained reduced irrespective of
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patients’ age. Reduced total brain perfusion predicted a
decrease in cortical thickness whereas antihypertensive
therapy was unrelated to total cerebral perfusion or cor-
tical thickness [44].
Brain regions which are particularly vulnerable to al-
terations with advanced age and increased BP involve
the prefrontal cortex, hippocampus, inferior temporal
cortex and inferior parietal lobule [40, 45–47]. This ob-
servation indicates that high BP alters grey matter struc-
ture by age-independent mechanisms.
Changes in white matter commonly occur in the eld-
erly, however the mechanisms underlying their decrease
are not fully understood. Cerebral small vessel disease
importantly contributes to a reduction in white matter
[48] which has been shown to be associated with an in-
creased risk of stroke, cognitive dysfunction, dementia
and death [49]. Hypertension per se plays a causative
role in the development of cerebral small vessel disease
resulting in lacunar infarcts [50].
Large artery remodeling is another potential mechan-
ism related with cognitive decline. Increased pulse pres-
sure and arterial stiffness which are a hallmark of
hypertension have been linked to white matter degrad-
ation, cognitive dysfunction and dementia [51, 52].
Hypertension-related cerebral white matter degradation
has been particularly found in the frontal lobe [49].
Additionally, accumulation of beta amyloid protein
in the brain related with high BP could be a potential
mechanism that connects BP level and cognitive
dysfunction [53].
Activation of the renin-angiotensin-aldosterone sys-
tem and oxidative stress are further mechanisms im-
plicated in hypertension-related cognitive dysfunction
[54, 55]. Endothelial dysfunction which is a common
feature of hypertension leads to endothelium-
mediated constriction and brain damage [56]. The al-
terations in vasodilator mechanisms including nitric
oxide, epoxyeicosatrienoic acids and ion channels ad-
versely impact endothelial function [54]. Hypertension
induces blood–brain barrier damage through direct
effect on oxidative stress, inflammation and vasoactive
substances [54]. Consequently, neurons are more vul-
nerable to cytotoxic molecules leading to neuronal
loss, white matter degradation, cognitive decline and
impaired recovery following cerebral ischemia [54].
Antihypertensive therapy and cognitive function
While several well-designed randomized controlled trials
reported the favorable influence of antihypertensive ther-
apy in the prevention or slowing of cognitive deterior-
ation, its preventive efficacy disputable.
A meta-analysis that included 15,936 hypertensive
subjects with average age of 75.4 years and BP levels of
171/86 mmHg across the studies failed to confirm that
lowering BP in late-life prevents the development of de-
mentia or cognitive impairment in hypertensive subjects
without a history of cerebrovascular disease [57]. On the
contrary, the well-known PROGRESS (Perindopril
Protection Against Recurrent Stroke Study) [58] and
Syst-Eur (Systolic Hypertension in Europe) trials [59]
have demonstrated a significant reduction in stroke-
related cognitive decline. The interest for the effect of
BP reduction on cognitive decline in middle-aged hyper-
tensive patients is increasing [60]. The Syst-Eur study
reported a 50 % reduction in incident dementia during
2-year follow-up period in subjects older than 60 years
[59]. Hypertensive middle-aged patients should be rou-
tinely tested for cognitive dysfunction because it may be
an early predictor of dementia and antihypertensive
treatment could slow cognitive decline in this patients.
More recently, another interesting observation
comes from a meta-analysis comparing the effective-
ness of different antihypertensive drug classes on the
incidence of dementia and cognitive function [61].
Antihypertensive therapy was associated with favor-
able effects on cognitive function [effect size 0.05,
95 % confidence interval: 0.02–0.07] irrespective of
drug classes. The risk of all-cause dementia was re-
duced by 9 % following BP lowering therapy when
compared to the control group (hazard ratio 0.91,
95 % CI: 0.89–0.94) [61]. While no significant
changes in average BP levels were noted across the
various antihypertensive drug classes, angiotensin II
receptor blockers (ARB) were superior to placebo in
improving overall cognition and were more effective
than β-blockers, diuretics and angiotensin-converting
enzyme inhibitors (ACEI) [61].
Several reasons have been suggested for the differ-
ent cognitive function responses to antihypertensive
medication and a resultant lack of coherent recom-
mendation to support the use of any specific drug
class in the prevention or slowing cognitive decline
[62]. No previous studies have been designed specific-
ally to focus on cognition, instead were concentrated
on elderly populations with low risk or minimal base-
line cognitive impairment and/or white matter lesions
with no long-term follow-up.
Studies regarding the influence of different antihyper-
tensive agents on cognitive function were mainly focused
on the effect of the blockers of the renin-angiotensin-
aldosterone (RAAS) and calcium channel blockers.
These investigations showed the favorable effect of
RAAS and calcium channel blockers on mental status,
which seems to be more pronounced than in other anti-
hypertensive groups. However, we need randomized tri-
als that would provide answer on this important
question. Possibly substudies of the SPRINT study will
give satisfactory response.
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Renin-angiotensin-aldosterone system antagonists
The activity of the RAAS system has been shown to be
implicated in cognitive decline and dementia. Indeed,
higher levels of circulating aldosterone were related with
impaired cerebral function in older hypertensive patients
[55]. Activation of angiotensin 1 receptor is associated
with inflammation, blood–brain barrier damage and a
decrease in blood brain flow. In this context, an inhib-
ition of the RAAS in the hippocampus (which plays a
significant part in cognition) using blood–brain barrier-
penetrating RAAS inhibitors may have favorable effects
in preventing cognitive decline [63]. Therapy with ARBs
and ACEIs, particularly using brain-penetrating drugs
such as captopril, perindopril and telmisartan appears to
improve blood–brain barrier function, increase cerebral
blood flow and reduce inflammation.
Angiotensin-converting enzyme inhibitors
ACEIs have been found to reduce the accumulation of
amyloid β (Aβ) peptides through substance P that poten-
tially may degrade brain Aβ peptide and increase the
acetylcholine [64]. This drug class can also decrease
neuronal injury by an anti-oxidative pathway. Given that
ACE has been found to be overexpressed in the hippo-
campus, frontal cortex, and caudate nucleus in patients
with AD [65], ACEI could be of clinical benefits in this
patient cohort.
The HOPE (Heart Outcomes Prevention Evaluation)
trial followed over 4.5 years 9297 patients with vascular
diseases and demonstrated a 41 % decrease in stroke-
related cognitive decline following therapy with ramipril
when compared to placebo [66]. Although a relatively
modest reduction in SBP/DBP (3.8/2.8 mmHg) levels
was achieved, the positive effect was especially evident
in regards to cognition and language disorders.
In the PROGRESS trial which involved 6105 patients
with cerebrovascular disease, treatment with perindopril
and indapamide for 4 years reduced the relative risk of
cognitive decline by 19 % (95 % CI: 4 to 32 %) in the
total population and 45 % in patients with recurrent
strokes (95 % CI: 21 to 61 %) [58]. In the total popula-
tion the risk of dementia also decreased by 12 % (95 %
CI: −8 to 28 %) and by 34 % in patients with recurrent
strokes (95 % CI: 3 to 55 %). These beneficial effects of
perindopril and indapamide therapy on dementia and
cognition were noticed irrespective of the history of
hypertension including both hypertensive and non-
hypertensive patients. A significant reduction in the risk
of dementia (by 23 %; 95 % CI: 0 to 41 %) was achieved
with dual therapy accompanied by a substantial reduc-
tion in BP (−12/5 mmHg for SBP/DBP) but not mono-
therapy (−8 %; 95 % CI = −48 to 21 %) resulting in a
lower BP reduction (−5/3 mmHg for SBP/DBP) [58].
Another interesting observation from a randomized
study has demonstrated that ACEIs which specifically
penetrate the blood–brain barrier (perindopril, capto-
pril) may be more effective in slowing cognitive de-
cline in mild to moderate AD patients when
compared to non-brain-penetrating ACEIs or calcium
channel blockers [67].
Angiotensin II receptor blocker
While ARBs may have a neuroprotective effect via cross-
ing the blood–brain barrier and increasing brain blood
flow, not all studies have proven this benefit. The
SCOPE (Study on Cognition and Prognosis in the Eld-
erly) trial included 4964 hypertensives aged 70–89 with
SBP and DBP of 160–170/90–99 mmHg followed over
3.97 years [68]. In this study, the effect of candesartan
on dementia and/or cognitive decline was not dissimilar
to that of placebo [68].
Another prospective study of 819,491 male partici-
pants (98 %) aged ≥65 has shown that time to incident
and deterioration of AD or dementia were significantly
reduced with ARBs comparing to ACEIs or other CV
drugs [69].
Further supportive evidence for the use of ARBs in
cognitive decline comes from a randomized study of 160
patients (76 men, 84 women) aged 61–75 years which
compared the effects of telmisartan/hydrochlorothiazide
(HTZ) to lisinopril/HTZ on cognitive function and am-
bulatory BP levels [70]. The greater BP lowering effects
achieved with the telmisartan/HTZ combination was ac-
companied by an improvement in some of the compo-
nents of cognitive function, particularly episodic
memory and visuospatial abilities at both 12 and
24 weeks of follow-up. In contrast, no significant
changes in any of the cognitive function test scores were
observed following treatment with lisinopril/HCTZ at
any time of the study [70].
Finally, a large meta-analysis that included 19 random-
ized trials (n = 18,515) and 11 studies (n = 831,674) of
patients with hypertension without previous cerebrovas-
cular disorders demonstrated that antihypertensive treat-
ment has favorable effects on cognitive decline, however
this benefit may differ between drug classes with the
most pronounced effect achieved with ARBs [61]. In this
context, further longer-term studies are needed to deter-
mine the effectiveness of ARBs in reducing the incidence
of dementia.
Aldosterone antagonists
Very recently, the association of aldosterone and renin
levels with cognitive and cerebrovascular measures was
demonstrated in a cohort of 47 subjects with mean age
of 71 who were followed over a 1 year of antihyperten-
sive therapy [55]. While higher levels of aldosterone at
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baseline were associated with decreased cerebrovascular
function in hypertension, these effects were unrelated to
the type of antihypertensive therapy or the degree of
changes in aldosterone levels. Unlike aldosterone, levels
of plasma renin activity bore no association with cogni-
tive measures [55].
In line with this observation, increased plasma aldos-
terone concentration has been linked to impaired cogni-
tive function in hypertensive patients [71]. Although
only shown in a small number of patients (n = 7), ther-
apy with aldosterone antagonists (i.e. spironolactone and
eplerenone) has led to an improvement in the mini-
mental state examination in treated patients when com-
pared to controls [71].
The relationship between the protective effects of
using BP lowering drugs and risk of AD was investigated
in the elderly participants of the Cache County Study
[72]. Although the use of any antihypertensive medica-
tion reduced the incidence of AD, the greatest effect was
observed using potassium-sparing diuretics with more
than a 70 % reduction in risk of AD [72].
While these findings are promising, the role that ex-
cessive aldosterone release on neurocognitive function
merits further investigation. Likewise, whether mineral
corticoid receptor blockade may improve cognitive func-
tion beyond CV protection needs to be confirmed in lar-
ger randomized clinical trials.
Calcium channel blockers
Intracellular calcium homeostasis is another potential
mechanism involved in cognitive function. Evidence sug-
gests that aging impairs ability of the brain intracellular
calcium degradation which is likely to induce cellular
damage leading to neural death and resultant cognitive
dysfunction. Indeed, 3 months therapy with nimodipine
commencing 7–14 days after cerebral infarction resulted
in memory improvement [73]. Further supportive find-
ings for the neuroprotective effects of calcium antago-
nists have been demonstrated in 1241 elderly
hypertensive patients with memory impairment [74].
The use of calcium antagonists decreased the risk of
cognitive impairment and AD independently of BP levels
when compared to patients not receiving calcium
blockers [74]. The long-term effects of antihypertensive
therapy initiated with a long-acting dihydropinidine
(nitrendypine) has been demonstrated in the double-
blind, placebo-controlled Syst-Eur trail in which the inci-
dence of dementia was reduced by 55 % [59].
Diuretics
Determining the exact effects of diuretics on cognitive
function remain challenging as most previous studies
applied them as concomitant antihypertensive agents
rather than monotherapy.
In the Syst-Eur trial HTZ was added to nitrendipine
and/or ACEI (enalapril) and indicated a reduced risk of
dementia following the long-term therapy [59]. The
PROGRESS study used indapamide in combination with
perindopril with a resulting decrease in the risk of de-
mentia and cognitive decline after recurrent stroke when
compared to perindopril alone or placebo [58]. However,
the Systolic Hypertension in the Elderly Program trial
did not find difference in the occurrence of cognitive
dysfunction in patients taking active treatment (low-dose
diuretic and/or beta blockers) or placebo [75].
Beta-adrenergic blocking agents
The influence of β-blockers with their potential benefi-
cial effects on cognitive function has not yet been clari-
fied with conflicting findings reported from different
studies.
One of the major limitations of previous studies is that
β-blockers are not commonly used as monotherapy in
the elderly but often in combination with ACEI/ARB,
calcium channel blockers and/or diuretics.
Available evidence suggests that a reduction in the in-
cidence of AD in participants with normal cognition ap-
pears to be achieved with all antihypertensive drug
classes including β-blockers [76]. However, the neuro-
protective effects of β-blockers seemed to be inferior
when compared to other classes [76].
On the contrary, the Honolulu-Asia Aging Study
which included 2197 hypertensive males (mean age
77 years) has found that the use of β-blockers alone was
related with a decreased risk of cognitive declining [77].
The efficacy of β-blockers in slowing cognitive impair-
ment was more pronounced in men with diabetes and
those older than 75 years and with pulse pressure
≥70 mm Hg. In contrast, the use of diuretics, calcium
channel blockers, ACEIs or vasodilators alone failed to
demonstrate any cognitive improvement [77]. However,
this was not confirmed by another cognitive randomized
placebo-controlled sub-study which demonstrated no
difference between the initiation of treatment with β-
blocker, diuretic or placebo on the change of cognitive
function over 54 months in hypertensive older adults
[78]. Whether differences in the efficacy of β-blockers
on cognitive function are related to specific drug proper-
ties, selectivity, pharmacokinetics or study cohorts re-
quires further investigation.
Conclusion
While the contribution of hypertension to cognitive dys-
function and dementia is well-recognized, the use of an-
tihypertensive approaches for the prevention of cognitive
decline continues to be debated. In view of the global
burden of hypertension, the aging population, the low
quality of life associated with cognitive decline and/or
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dementia resulting in increasing costs to health care sys-
tems, there is rationale for improving BP control. Special
attention should focused on the treatment of midlife
hypertension which is likely to reduce the incidence of
dementia in late-life which is beyond cardiac, renal and
vascular protection. Evidence supports the use of any BP
lowering drugs with greater efficacy leaning to treatment
with ARBs, ACEIs, calcium channel blockers and aldos-
terone antagonists for the prevention of cognitive de-
cline in hypertensive patients. Combination of two or
more antihypertensive agents is preferable to monother-
apy due to additive and synergistic effects on BP control,
prevention of stroke and possibly cognitive impairment.
Notably, cautious hypertension management is required
in the elderly and very old frail subjects as per the recent
expert opinion recommendations [79]. Given that there
is potential for (1) increasing incidence of dementia and
mortality in old elderly with low BP achieved with anti-
hypertensive drug therapy and (2) worsening further
prognosis in hypertensive patients with existing impaired
cognition, a therapeutic approach in this cohort needs to
be established. Cognitive tests should be implemented
into clinical practice, particularly in the old hyperten-
sives prior to commencing therapy.
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